Alexion Pharmaceuticals
Headquartered in Cheshire, Connecticut (USA), Alexion is global biopharmaceutical company focused on the development and delivery of life-transforming therapies for patients with severe and life-threatening rare disorders.
Financial Data
-
31st Dec 18 Source: CRO
- €2.3 billion turnover
-
€1.3 billion
profit - 500 employees
-
31st Dec 17 Source: Estimated
- €321.6 million turnover
- 300 employees
- 4 more years available »
Ranking
By Turnover
(€2.3 billion)- 49th in Top Companies
- 9th in Health
- 7th in Pharma
By Employees
(500)- 367th in Top Companies
- 55th in Health
- 35th in Pharma
- 500
- €2.3 billion
Employees
- Shane Doyle Senior vice president
Latest News
- Jun 01 Global stocks climb near three-month highs as rebound hopes grow
- Jun 01 Two prominent business leaders in planning row with neighbour
- Jun 01 ASL Aviation Holdings chief to retire after 22 years in post
- Jun 01 Small businesses focus on training in traditional skills as Covid-19 crisis bites
- Jun 01 Credit Suisse wins control over Chinese securities joint venture